SCHEMBL17312335

SCHEMBL17312335

Cc1ccc2oc(=O)n(Cc3ccc(OCC(=O)NN)c(O)c3)c2c1

nearest known ligand 0.59

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
▸ TSHR P16473 6/20 0.59
▸ HTT P42858 4/20 0.59
▸ SMN1; SMN2 Q16637 4/20 0.59
▸ LMNA P02545 4/20 0.59
▸ ALDH1A1 P00352 2/20 0.59
▸ KDM4E B2RXH2 1/20 0.56
▸ MIF P14174 5/20 0.54
▸ MAPK1 P28482 2/20 0.53
▸ GAA P10253 1/20 0.53
▸ KMT2A Q03164 2/20 0.53
▸ MEN1 O00255 1/20 0.53
▸ POLB P06746 1/20 0.53
▸ CD74 P04233 2/20 0.51
▸ L3MBTL1 Q9Y468 1/20 0.47
▸ HPGD P15428 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16296741 0.88 TSHR (0.63) TSHRHTTSMN1; SMN2LMNAALDH1A1
SCHEMBL16305142 0.88 TSHR (0.48) TSHRHTTSMN1; SMN2LMNAALDH1A1
SCHEMBL18402538 0.87 TSHR (0.62) TSHRHTTSMN1; SMN2LMNAALDH1A1
SCHEMBL18402541 0.87 TSHR (0.65) TSHRHTTSMN1; SMN2LMNAALDH1A1
SCHEMBL17327981 0.83 TSHR (0.51) TSHRHTTSMN1; SMN2LMNAALDH1A1
SCHEMBL16294776 0.80 TSHR (0.44) TSHRHTTSMN1; SMN2LMNAALDH1A1
SCHEMBL2757835 0.79 MIF (0.71) TSHRHTTSMN1; SMN2LMNAALDH1A1
SCHEMBL17327982 0.78 TSHR (0.45) TSHRHTTSMN1; SMN2LMNAALDH1A1
SCHEMBL17328027 0.77 TSHR (0.44) TSHRHTTSMN1; SMN2LMNAALDH1A1
SCHEMBL16296797 0.77 TSHR (0.78) TSHRHTTSMN1; SMN2LMNAALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9549988-B2 Pharmaceutical compounds targeted by MIF affinity-tethered moieties RJS Biologics (US) 2017-01-24 — — US disclosed
US-9549988-B2 Pharmaceutical compounds targeted by MIF affinity-tethered moieties RJS Biologics (US) 2017-01-24 — — US disclosed
US-9549988-B2 Pharmaceutical compounds targeted by MIF affinity-tethered moieties RJS Biologics (US) 2017-01-24 — — US disclosed
US-20150352217-A1 Pharmaceutical Compounds Targeted by MIF Affinity-Tethered Moieties RJS BIOLOGICS LLC 2015-12-10 — — US disclosed
US-20150352217-A1 Pharmaceutical Compounds Targeted by MIF Affinity-Tethered Moieties RJS BIOLOGICS LLC 2015-12-10 — — US disclosed
US-20150352217-A1 Pharmaceutical Compounds Targeted by MIF Affinity-Tethered Moieties RJS BIOLOGICS LLC 2015-12-10 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150352217-A1 Pharmaceutical Compounds Targeted by MIF Affinity-Tethered Moieties MIF, HMGB2, HMGB1 TSHR 3054/4885HTT 1057/4885SMN1; SMN2 3667/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback